Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Another case against the midnight snack

December 1, 2014 – 5:00 pm | Edit Post

LA JOLLA–These days, with the abundance of artificial light, TV, tablets and smartphones, adults and children alike are burning the midnight oil. What they are not burning is calories: with later bedtimes comes the tendency to eat.

Tocagen Inc. Appoints To The Board Of Directors

December 1, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 /PRNewswire/ –Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Franklin M. Berger, CFA, has been appointed to the board of directors. Mr. Berger…

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Completes Enrollment In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia

December 1, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 /PRNewswire/ –MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine…

Tocagen Inc. Appoints To The Board Of Directors

December 1, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 /PRNewswire/ –Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Franklin M. Berger, CFA, has been appointed to the board of directors. Mr. Berger…

OncoSec Medical Inc. Collaborates With PerkinElmer, Inc. And University of California, Los Angeles (UCLA) To Evaluate Patient-Selection Biomarker In Immunotherapy

December 1, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced a collaboration with PerkinElmer, Inc. and the University of California, Los Angeles (UCLA) to help researchers develop biomarker tests to evaluate a patients immune response to cancer. This research supports the ongoing shift in oncology toward therapeutic…

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) Completes Enrollment In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia

December 1, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 /PRNewswire/ –MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that it has completed enrollment in a Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine…

SpectraScience, Inc. Appoints To The Board of Directors

December 1, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – December 02, 2014) – SpectraScience, Inc. (OTCQB: SCIE), a San Diego-based medical device company, today announced that its Board of Directors has appointed Rand Mulford to its Board.Michael Oliver, President and Chief Executive Officer, said, “We are fortunate that Rand…

Exercise following bariatric surgery provides health benefits

December 1, 2014 – 3:00 pm | Edit Post

Exercise after weight-loss surgery may prevent type 2 diabetes.

Exercise following bariatric surgery provides health benefits

December 1, 2014 – 3:00 pm | Edit Post

Exercise after weight-loss surgery may prevent type 2 diabetes.

Quidel Announces Proposed Offering of $150 Million of Convertible Senior Notes

December 1, 2014 – 2:33 pm | Edit Post

SAN DIEGO, CA–(Marketwired – Dec 1, 2014) – Quidel Corporation ( NASDAQ : QDEL ), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the proposed underwritten public offering of $150 million aggregate principal amount of its convertible senior notes due 2020 (the “notes”). Quidel also expects to grant the underwriters of the notes a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of the notes, solely to cover over-allotments, if any. BofA Merrill Lynch and J.P. Morgan will act as book-running managers for the proposed notes offering.